Robert Marcus
Sanofi S.A.
8 Papers
1 Citations
Robert Marcus is an academic researcher from Sanofi S.A.. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Michael Herold,Eva Hoster,Annelies Janssens,Helen McCarthy,Alessandra Tedeschi,Christopher Pocock,András Rosta,Marek Trneny,Tina Nielsen,Andrea Knapp,Wolfgang Hiddemann,Robert Marcus +11 more
TL;DR: G-chemotherapy cannot be recommended as first-line treatment for MZL and both arms had a higher incidence of grade 3–5 and serious AEs than patients with follicular lymphoma (GALLIUM), with G-Chemotherapy being less tolerable than R-che motherapy.
15
S206: obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the gallium study
William Townsend,Wolfgang Hiddemann,Christian Buske,Guillaume Cartron,Dennis D. Cunningham,Martin J. S. Dyer,John G. Gribben,E. Phillips,M. Dreyling,John F. Seymour,Andrew Grigg,Ting-Yu Lin,Xiaonan Hong,D. Kingbiel,Tina Nielsen,Andrea Knapp,Michael Herold,Robert Marcus +17 more
TL;DR: Townsend et al. as mentioned in this paper reported the final analysis of the GALLIUM study after a median observation time of 8 years, where the primary endpoint was investigator-assessed PFS; secondary endpoints included time-to-next anti-lymphoma treatment (TTNLT), overall survival (OS) and incidence of adverse events (AEs).
10
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.
Carla Casulo,Michael Herold,Wolfgang Hiddemann,Sunil Iyengar,Robert Marcus,John F. Seymour,Aino Launonen,Andrea Knapp,Tina Nielsen,Farheen Mir +9 more
TL;DR: In the phase III, GALLIUM study as discussed by the authorsOWL CANCER (GALLIUM) trial, male sex and elevated baseline levels of serum LDH and B2M were significant risk factors for HT.
10
An optimized workflow for single-cell transcriptomics and repertoire profiling of purified lymphocytes from clinical samples.
Richa Hanamsagar,Timothy Reizis,Mathew Chamberlain,Robert Marcus,Frank O. Nestle,Emanuele de Rinaldis,Virginia Savova +6 more
TL;DR: This work explores sample preparation techniques relevant to a range of clinically relevant scenarios, where SC gene expression and repertoire analysis are applied to a cryopreserved sample derived from a small amount of blood, with unknown or partially known preservation history.
A novel cell type negatively associated with secondary autoimmunity in alemtuzumab-treated patients is revealed through single-cell longitudinal analysis of clinical trial samples
Virginia Savova,Richa Hanamsagar,Mathew Chamberlain,Srinivas Shankara,Robert Marcus,Darren P Baker,Klinger Kw,Evis Havari,Frank Nestle,Emanuele de Rinaldis +9 more
TL;DR: A longitudinal single-cell analysis of PBMCs in a small subset of alemtuzumab-treated patients from the phase 3 CARE-MS I (CAMMS323) study was carried out and identified a novel platelet lineage cell negatively associated with thyroid autoimmunity.